Titan Pharmaceuticals Stock

TTNP

US8883147055

Delayed Nasdaq Other stock markets 16:42:42 23/07/2026 +03			5-day change	1st Jan Change
0.9170 ^USD	+0.07%		+16.29%	-80.11%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.37M 4.99M 4.58M 8.64M 592M 8.76M 59.42M 23.26M 290M 23.02M 22.52M 1B	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.89M 2.69M 2.47M 4.65M 319M 4.72M 31.99M 12.52M 156M 12.39M 12.13M 538M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news : Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
01/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
14/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
14/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
11/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
01/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
20/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	TITAN PHARMACEUTICALS : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
27/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
23/07/26	$0.9170	+0.07%	1,958
22/07/26	$0.9164	-12.72%	9,804
21/07/26	$1.050	+2.44%	62,056
20/07/26	$1.025	+11.85%	44,652
17/07/26	$0.9164	+0.70%	38,129

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

1 year	0.92	5.35
3 years	0	14.8
5 years	0	47.6
10 years	0	23,040.03

	2023	2024
Net sales	184K 161K 150K 138K 259K 17.76M 263K 1.78M 698K 8.69M 691K 676K 30.01M	-
Net income	-5.57M -4.88M -4.53M -4.16M -7.84M -537M -7.96M -53.96M -21.12M -263M -20.91M -20.45M -908M	-4.71M -4.12M -3.83M -3.52M -6.63M -454M -6.73M -45.6M -17.85M -222M -17.67M -17.29M -768M
Net Debt	-6.2M -5.43M -5.04M -4.63M -8.73M -598M -8.85M -60.03M -23.5M -293M -23.26M -22.75M -1.01B	-2.83M -2.48M -2.3M -2.12M -3.99M -273M -4.05M -27.43M -10.74M -134M -10.63M -10.4M -462M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news : Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Course Extremes

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.07%
Current month	-80.11%
Current year	-80.11%